Maxim initiated coverage of Kazia Therapeutics (KZIA) with a Buy rating and $3 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZIA:
- Kazia Therapeutics Highlights Ongoing Oncology Drug Development Progress
- Kazia Therapeutics Launches Innovative Breast Cancer Trial with Paxalisib and Immunotherapy
- Kazia Therapeutics launches trial of paxalisib/immunotherapy combination
- Kazia Therapeutics Issues Prefunded Warrant for ADS Purchase
- Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering